These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15458462)

  • 21. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients.
    Yongsiri S; Thammakumpee J; Prongnamchai S; Tengpraettanakorn P; Chueansuwan R; Tangjaturonrasme S; Dinchuthai P
    Ther Apher Dial; 2015 Feb; 19(1):81-6. PubMed ID: 25196890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis.
    Baker WL; White WB
    Ann Pharmacother; 2012 Jun; 46(6):889-94. PubMed ID: 22669801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary prostasin: a candidate marker of epithelial sodium channel activation in humans.
    Olivieri O; Castagna A; Guarini P; Chiecchi L; Sabaini G; Pizzolo F; Corrocher R; Righetti PG
    Hypertension; 2005 Oct; 46(4):683-8. PubMed ID: 16172430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
    Matthesen SK; Larsen T; Vase H; Lauridsen TG; Jensen JM; Pedersen EB
    Clin Exp Hypertens; 2013; 35(5):313-24. PubMed ID: 22966789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial impact of spironolactone in diabetic nephropathy.
    Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Rossing P; Tarnow L; Parving HH
    Kidney Int; 2005 Dec; 68(6):2829-36. PubMed ID: 16316360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice.
    Schulz-Baldes A; Berger S; Grahammer F; Warth R; Goldschmidt I; Peters J; Schütz G; Greger R; Bleich M
    Pflugers Arch; 2001 Nov; 443(2):297-305. PubMed ID: 11713657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-acetylcysteine attenuates the progression of chronic renal failure.
    Shimizu MH; Coimbra TM; de Araujo M; Menezes LF; Seguro AC
    Kidney Int; 2005 Nov; 68(5):2208-17. PubMed ID: 16221220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
    Joffe HV; Kwong RY; Gerhard-Herman MD; Rice C; Feldman K; Adler GK
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2552-8. PubMed ID: 17488800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients.
    Flevari P; Kalogeropoulou S; Drakou A; Leftheriotis D; Panou F; Lekakis J; Kremastinos D; Vlahakos DV
    J Hypertens; 2013 Jun; 31(6):1239-44. PubMed ID: 23552120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a simultaneous potassium and carbohydrate load on extrarenal K homeostasis in end-stage renal failure.
    Alvo M; Krsulovic P; Fernández V; Espinoza AM; Escobar M; Marusic ET
    Nephron; 1989; 53(2):133-7. PubMed ID: 2682302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-aldosterone response, urinary Na/K ratio and growth in pseudohypoaldosteronism patients with mutations in epithelial sodium channel (ENaC) subunit genes.
    Hanukoglu A; Edelheit O; Shriki Y; Gizewska M; Dascal N; Hanukoglu I
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):268-74. PubMed ID: 18634878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of aldosterone in potassium tolerance: studies in anephric humans.
    Sugarman A; Brown RS
    Kidney Int; 1988 Sep; 34(3):397-403. PubMed ID: 3172648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
    Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome.
    Drüppel V; Kusche-Vihrog K; Grossmann C; Gekle M; Kasprzak B; Brand E; Pavenstädt H; Oberleithner H; Kliche K
    FASEB J; 2013 Sep; 27(9):3652-9. PubMed ID: 23729588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.